Correction to: Rare Adverse Events with Programmed Death-1 and Programmed Death-Ligand 1 Inhibitors: Justification and Rationale for a Systematic Review

Caleb J. Smith¹ · Yahya Almodallal² · Aminah Jatoi²

Published online: 1 July 2021

© Springer Science+Business Media, LLC, part of Springer Nature 2021

Correction to: Current Oncology Reports

<https://doi.org/10.1007/s11912-021-01089-9>

The original version of this article unfortunately contained a mistake in the article title. It should read “Programmed Death-Ligand 1 Inhibitors,” not “Programmed Death-1 Ligand Inhibitors”.

The original article has been corrected.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at <https://doi.org/10.1007/s11912-021-01089-9>

✉ Aminah Jatoi
jatoi.aminah@mayo.edu

¹ Department of Medicine, Mayo Clinic, Rochester, MN, USA

² Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55902, USA